“The drug development landscape in Parkinson’s” by Dr Kevin McFarthing - video recording now available

[Michel0220]

Thank you to all of you who joined us on Monday to listen to Dr Kevin McFarthing talk to us about “The drug development landscape in Parkinson’s”. Kevin's presentation provides a comprehensive overview of Parkinson's research but also focuses specifically on:

- ENT-01, derived from the liver of the dogfish shark. It has been successfully tested in constipation, with some effects in PD psychosis, and in a trial for PD dementia.

- Exenatide, one of a series of compounds originally discovered in the saliva of lizards, GLP-1 agonists. It is currently used in type 2 diabetes.

- Anavex 2-73, a drug that stimulates the activity of chaperone proteins.

The video recording can be found on our YouTube channel:

youtube.com/channel/UCN2A0v...

Please subscribe to our channel to get automated updates of future videos.

-------------

Originally a PhD biochemist, Dr Kevin McFarthing’s career included R&D leadership positions in life sciences research products with Amersham, diagnostics with Serono and consumer healthcare with Reckitt Benckiser.

He is joint editor of the Clinical Trial Highlights section of the Journal of Parkinson’s Disease and a member of the Research Committee of Cure Parkinson’s.

Kevin collates the Parkinson’s Hope List (bit.ly/ParkinsonsHopeList), a database of potential therapies in research and clinical stages.

He also chairs the Patient and Public Involvement and Engagement group for the Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease program.

Kevin was diagnosed with Parkinson’s in 2012 at the age of 55.